首页> 美国卫生研究院文献>Journal of Korean Medical Science >The Efficacy of Hepatic Resection after Neoadjuvant Transarterial Chemoembolization (TACE) and Radiation Therapy in Hepatocellular Carcinoma Greater Than 5 cm in Size
【2h】

The Efficacy of Hepatic Resection after Neoadjuvant Transarterial Chemoembolization (TACE) and Radiation Therapy in Hepatocellular Carcinoma Greater Than 5 cm in Size

机译:新辅助经动脉化疗栓塞(TACE)和放射治疗在大于5 cm的肝细胞癌中的肝切除效果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In cases of large hepatocellular carcinoma (HCC), neoadjuvant treatment such as transarterial chemoembolization (TACE) and radiation therapy can be performed. The aim of this study was to evaluate the outcome of these treatments prior to hepatic resection. Between January 1994 and May 2007, 16 patients with HCC greater than 5 cm in size were treated with TACE and radiation therapy prior to hepatic resection. The clinicopathologic factors were reviewed retrospectively. Of the 16 patients, there were 14 men and two women, and the median age was 52.5 yr. TACE was performed three times in average, and the median radiation dosage was 45 Gy. The median diameter of tumor on specimen was 9.0 cm. The degree of tumor necrosis was more than 90% in 14 patients. The median survival time was 13.3 months. Five patients had survived more than 2 yr and there were two patients who had survived more than 5 yr. Although the prognosis of large HCC treated with neoadjuvant therapy is not satisfactory, some showed long-term survival loger than 5 yr. Further research will be required to examine the survival and disease control effect in a prospective randomized study.
机译:在大肝细胞癌(HCC)的情况下,可以进行新辅助治疗,例如经动脉化学栓塞(TACE)和放射疗法。这项研究的目的是评估肝切除术之前这些治疗的结果。在1994年1月至2007年5月之间,有16例HCC大于5厘米的HCC患者在肝切除之前接受了TACE和放射治疗。回顾性分析临床病理因素。在16例患者中,男14例,女2例,中位年龄为52.5岁。 TACE平均进行3次,中位辐射剂量为45 Gy。标本上肿瘤的中值直径为9.0 cm。 14例患者的肿瘤坏死程度超过90%。中位生存时间为13.3个月。 5名患者的生存期超过2年,有2名患者的生存期超过5年。尽管接受新辅助疗法治疗的大型HCC的预后并不令人满意,但仍有一些患者的长期生存记录超过5年。在一项前瞻性随机研究中,将需要进一步的研究来检查其生存率和疾病控制效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号